10,183 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by Brooktree Capital Management

Brooktree Capital Management bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 10,183 shares of the medical device company’s stock, valued at approximately $683,000. DexCom comprises approximately 0.6% of Brooktree Capital Management’s portfolio, making the stock its 22nd biggest position.

Other institutional investors also recently added to or reduced their stakes in the company. Taylor Frigon Capital Management LLC lifted its stake in DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after purchasing an additional 11,075 shares during the last quarter. National Pension Service raised its holdings in DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after purchasing an additional 37,363 shares in the last quarter. Intact Investment Management Inc. purchased a new stake in shares of DexCom during the 3rd quarter worth approximately $650,000. Waters Parkerson & CO. LLC lifted its position in shares of DexCom by 4.2% during the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after buying an additional 10,892 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of DexCom by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after buying an additional 49,076 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. lifted their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Sanford C. Bernstein lifted their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Morgan Stanley decreased their target price on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday, July 26th. Piper Sandler restated an “overweight” rating and set a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Finally, Robert W. Baird boosted their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Stock Up 0.3 %

Shares of DexCom stock opened at $72.75 on Thursday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a market cap of $28.42 billion, a P/E ratio of 43.43, a PEG ratio of 2.28 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a fifty day moving average of $69.72 and a two-hundred day moving average of $92.27.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.